Affidea Switzerland acquires Berner Urologen AG and expands its integrated urology services

Affidea Switzerland has acquired Berner Urologen AG, a leading urology practice with locations in Bern and Langenthal. The acquisition expands Affidea Switzerland’s medical offering in urology while further strengthening its presence in the Bern region. It also supports the company’s long-term strategy to broaden its medical services across additional regions of Switzerland. Affidea Switzerland is the national subsidiary of the pan-European Affidea Group, a leading provider of out-of-hospital community-based polyclinics, specialised oncological services and advanced diagnostic imaging in Europe. Prior to this acquisition, Affidea Switzerland was already well established across Switzerland, operating 39 centres and 12 laboratories, and working with more than 900 people, including over 150 physicians.

Berner Urologen AG was founded in 2021 by Dr Thomas von Rütte and Dr Tobias Gross and is a specialised urology provider with locations in Bern and Langenthal. The team comprises nine urologists supported by medical and administrative staff.

In addition to diagnostic assessments and conservative treatments, the company offers surgical and highly specialised urological procedures, including robot-assisted and open surgical techniques as well as modern endourological and microsurgical treatments. This further strengthens Affidea Switzerland’s network with additional clinical expertise and established care structures.

“In Affidea Switzerland, we have found a strong partner that shares our values and opens up new opportunities for us. Our patients will continue to receive the trusted care they know, while we will be able to further develop our urological services with the backing of a large network focused on quality and clinically-led systems,” says Tobias Gross of Berner Urologen AG.

“The partnership with Affidea marks an important milestone for our team. It provides stability, creates new development opportunities and enables us to further develop our locations in Bern and Langenthal over the long term,” adds Thomas von Rütte of Berner Urologen AG.

For Affidea Switzerland, the acquisition is an important step in the targeted expansion of its urology platform, further advancing integrated care pathways. It complements the existing urology network, including Uroviva centres across Zurich, Zug, Lucerne and Solothurn, enabling a more seamless patient journey from diagnosis through treatment and follow-up. With the addition of Berner Urologen AG, Affidea is extending this model into the canton of Bern, further enhancing access to coordinated, high-quality urology services.

“Berner Urologen AG is an excellent fit for Affidea Switzerland and represents an important step in the further development of our urology network. With this acquisition, we are strategically expanding our outpatient medical services and strengthening our presence in the Bern region,” says Marc-André Christinat, CEO of Affidea Switzerland.

Dr Charles Niehaus, Executive Director of the Affidea Group, adds: “This acquisition reflects how we are continuing to evolve our model of care, expanding our network of leading collaborative clinicians, moving beyond standalone services towards fully integrated, patient-centred pathways. In urology, this means connecting early diagnostics, specialist expertise and treatment within one coordinated ecosystem, improving both clinical outcomes and patient experience. Switzerland is a key market for Affidea, and this step strengthens our ability to scale high-quality, out-of-hospital care in a structured and sustainable way across Europe.”

Affidea’s legal advisors for the transaction were Niederer Kraft Frey AG, while EY provided finance & tax services.